Previous publications report simultaneous inhibition of PI3K/mTOR signaling using mTOR inhibitor Rapamycin (Rapa) and/or PI3K inhibitor LY294002 with N3a-p53-activation reinforced induction of p53-mediated apoptosis in CTCL cells [37]. This evidence concerns the gene TP53 and primary cutaneous T-cell non-Hodgkin lymphoma.